← Leaderboards
Joseph T Bruder
Genvec, Inc.
$2,184,286
Attributed
$2,184,286
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $599.7K · FY2005–12$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$2,184,286 · 5
By mechanism
R43$1,599,548 · 4
R44$584,738 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Cd8b1 Gene”
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Rama Rao Amara · Emory University$47,095,662
- Rafi Ahmed · Emory University$42,649,225
- Louis J. Picker · Oregon Health And Science University$26,538,123
- Eric Hunter · University Of Alabama At Birmingham$26,385,296
- Arlene H Sharpe · Harvard Medical School$25,020,892
Research focus
Cd8b1 GeneVaccine DevelopmentVectorMalaria VaccinesBaseTechnologyMalariaVaccinesAdenovirus VectorHealth PrioritiesT-LymphocyteCessation Of LifeSmall Business Innovation Research GrantStagingAntigensErythrocytesImmune ResponseResearch Clinical TestingResponseAnimal ModelAfrica South Of The SaharaProductionIn VitroLead
Grant awards (8)
Pre-erythrocytic Stage Antigen Discovery for Malaria Vaccine Development$300,000
R43 · FY2012 · AI · contact PI
High Throughput Genomics Screening for Malaria Antigen Discovery$300,000
R43 · FY2010 · AI · contact PI
High Throughput Genomics Screening for Malaria Antigen Discovery$300,000
R43 · FY2009 · AI · contact PI
Novel Ad5 Malaria Vaccine That Circumvents Pre-existing Ad5 Immunity$299,660
R43 · FY2009 · AI · contact PI
Novel Ad5 Malaria Vaccine That Circumvents Pre-existing Ad5 Immunity$299,889
R43 · FY2008 · AI · contact PI
Evaluation of High-Capacity Adenovectors in the Eye$369,329
R44 · FY2006 · EY · contact PI
Evaluation of High-Capacity Adenovectors in the Eye$215,409
R44 · FY2005 · EY
Evaluation of Adenovirus Vectors in the Eye$99,999
R43 · FY2003 · EY